Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
BMJ Open|October 10, 2025
PLAN-psoriasis: protocol for a randomised controlled feasibility trial comparing patient-led 'as-needed' treatment and therapeutic drug monitoring-guided treatment to continuous treatment for adults with clear or almost clear skin on risankizumab monotherapy for psoriasisWeiyu Ye, Kingsley Powell, Niamh Dooley, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2025
Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)Adrie Bekker, Navarat Panjasawatwong, Louise F Hill, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 14